A Double-Blind, Placebo-Controlled Study to Examine the Safety and Efficacy of Pimavanserin for the Treatment of Agitation and Aggression in Alzheimer's Disease

Trial Profile

A Double-Blind, Placebo-Controlled Study to Examine the Safety and Efficacy of Pimavanserin for the Treatment of Agitation and Aggression in Alzheimer's Disease

Recruiting
Phase of Trial: Phase II

Latest Information Update: 22 Apr 2017

At a glance

  • Drugs Pimavanserin (Primary)
  • Indications Aggression; Agitation
  • Focus Therapeutic Use
  • Sponsors Acadia Pharmaceuticals
  • Most Recent Events

    • 18 Apr 2017 Planned End Date changed from 19 Jan 2019 to 1 Jul 2019.
    • 09 Mar 2016 New trial record
    • 29 Feb 2016 According to an Acadia Pharmaceuticals media release, this trial is expected to start in the first half of 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top